2021
DOI: 10.1177/2515690x211039219
|View full text |Cite
|
Sign up to set email alerts
|

Systematic Review and Meta-Analysis of the Efficacy of MLC901 (NeuroAiD IITM) for Acute Ischemic Brain Injury in Animal Models

Abstract: Introduction. Moleac (MLC) 901 is a traditional Chinese medication approved by the Sino Food and Drug Administration in 2001 for treating stroke. This study aims to analyze the efficacy of MLC901 in animal stroke models after medial cerebral artery occlusion (MCAO). Methods. Literature selection was performed according to the guidelines of the Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA) 2015. Inclusion criteria for the experimental studies were the use of animal models,… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2

Citation Types

0
4
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
5

Relationship

0
5

Authors

Journals

citations
Cited by 5 publications
(4 citation statements)
references
References 27 publications
0
4
0
Order By: Relevance
“…Multiple studies have investigated the effects of MLC901 on motor function [ 21 , 23 , 35 ]. The administration of MLC901 enhanced motor performance in a rats model of ischemic stroke for seven days [ 19 ].…”
Section: Discussionmentioning
confidence: 99%
See 2 more Smart Citations
“…Multiple studies have investigated the effects of MLC901 on motor function [ 21 , 23 , 35 ]. The administration of MLC901 enhanced motor performance in a rats model of ischemic stroke for seven days [ 19 ].…”
Section: Discussionmentioning
confidence: 99%
“…According to a meta-analysis, the administration of MLC901 demonstrated significant improvements in infarct volume, brain BrdU expression, and neurological function as assessed by the Bederson Neurological Outcome Score in animal models of acute ischemic brain injury. MLC901 has been found to enhance the recovery process of acute ischemic brain injury [ 23 ]. The AIS examination demonstrated a 25% enhancement in AIS A and a 50% improvement in AIS B after administering conventional therapy with MLC901 [ 21 ].…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…MLC 901 has neuroprotective and neuroproliferative effects and has been extensively described during in vitro and in vivo experiments using animal models. The remarkable effect of MLC 901 lies in its neurogenesis and neurorestoration effects rather than its neuroprotective effects [ [25] , [26] , [27] ].…”
Section: Introductionmentioning
confidence: 99%